This is a StreetInsider.com Premium Only Page

Dynavax (DVAX) – PRNewswire

Nov 20, 2023 05:04 PM Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 2, 2023 04:01 PM Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance

Oct 26, 2023 04:15 PM Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

Oct 19, 2023 01:15 PM Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference

Sep 6, 2023 04:05 PM Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023 04:05 PM Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance

Jul 20, 2023 04:15 PM Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

May 30, 2023 04:15 PM Dynavax to Present at Upcoming Investor Conferences

May 8, 2023 04:15 PM Dynavax to Present at the JMP Securities Life Sciences Conference

May 2, 2023 04:05 PM Dynavax Reports First Quarter 2023 Financial Results

Apr 18, 2023 04:15 PM Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023

Mar 1, 2023 04:15 PM Dynavax to Present at the Cowen 43rd Annual Health Care Conference

Feb 28, 2023 08:00 AM Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine

Feb 23, 2023 04:05 PM Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance

Feb 9, 2023 04:15 PM Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

Jan 31, 2023 04:15 PM Dynavax Announces Uplisting to the Nasdaq Global Select Market

Jan 9, 2023 08:00 AM Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results

Nov 9, 2022 04:05 PM Dynavax to Present at Two Upcoming Investor Conferences

Nov 3, 2022 04:05 PM Dynavax Reports Third Quarter 2022 Financial Results

Oct 20, 2022 04:05 PM Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022

Oct 14, 2022 04:05 PM Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference

Sep 12, 2022 08:00 AM Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine

Sep 8, 2022 04:05 PM Dynavax to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 4, 2022 04:02 PM Dynavax Reports Second Quarter 2022 Financial Results

Jul 21, 2022 04:05 PM Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022

May 25, 2022 04:05 PM Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference

May 16, 2022 04:10 PM Dynavax to Present at the H.C. Wainwright Global Investment Conference

May 12, 2022 06:16 PM Independence Realty Trust Set to Join S&P MidCap 400; Alpha and Omega Semiconductor & Dynavax Technologies to Join S&P SmallCap 600

May 5, 2022 04:02 PM Dynavax Reports First Quarter 2022 Financial Results

Apr 21, 2022 04:05 PM Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022

Apr 5, 2022 04:02 PM Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 8, 2022 04:05 PM Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2022 04:05 PM Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 28, 2022 04:02 PM Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance

Feb 23, 2022 04:05 PM Dynavax to Present at the Cowen 42nd Annual Health Care Conference

Feb 16, 2022 04:05 PM Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

Feb 2, 2022 04:05 PM Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 10, 2022 08:00 AM Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate

Jan 7, 2022 04:05 PM Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2022 04:05 PM Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

Dec 28, 2021 11:34 AM COVID-19 Vaccine Developed by Biological E Using Dynavax's CpG 1018 Adjuvant Receives India DCGI Approval for Emergency Use

Dec 14, 2021 08:10 AM Elaine D. Sun Appointed to Dynavax Board of Directors

Dec 2, 2021 04:05 PM Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 18, 2021 04:10 PM Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference

Nov 4, 2021 04:02 PM Dynavax Reports Third Quarter 2021 Financial Results

Nov 2, 2021 04:10 PM Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 21, 2021 04:20 PM Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman

Oct 21, 2021 08:00 AM Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021

Oct 18, 2021 05:43 PM Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 18, 2021 02:27 AM COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial